남성 성선기능저하증 치료 시장 보고서 : 동향, 예측, 경쟁 분석(-2031년)

The future of the global male hypogonadism therapy market looks promising with opportunities in the hospitals and drugstores markets. The global male hypogonadism therapy market is expected to grow with a CAGR of 4.5% from 2025 to 2031. The major drivers for this market are the rising prevalence of male hypogonadism and the increased awareness & acceptance of male hormone therapy.

• Lucintel forecasts that, within the type category, parenteral will remain the largest segment over the forecast period due to increasing preference for stable, supervised dosing, long-lasting, and widely used.
• Within the application category, drugstores will remain the larger segment due to wide availability and convenience for consumers.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Male Hypogonadism Therapy Market

The global male hypogonadism therapy market is undergoing a transformation, driven by emerging trends that reflect technological advances, evolving patient needs, and shifts in healthcare systems. As male hypogonadism gains more recognition, innovative therapies and treatment approaches are being developed to address various facets of the condition. Below are five key trends that are shaping the market:

• Increased Adoption of Long-Acting Testosterone Therapies: Long-acting testosterone therapies, such as injectable testosterone and subcutaneous pellets, are gaining popularity due to their convenience and reduced frequency of administration. These treatments allow for sustained release of testosterone, providing stable hormone levels for patients. This shift is driven by the need for therapies that offer better patient compliance, particularly for individuals who struggle with daily or weekly treatments. The development of innovative formulations that require fewer injections or topical applications is expected to further fuel this trend, enhancing patient satisfaction and improving the overall efficacy of treatment.
• Rise of Personalized Medicine: Personalized medicine, which tailors treatment plans to the specific genetic makeup and health status of the individual, is becoming increasingly important in the male hypogonadism therapy market. With advancements in genetic testing and biomarkers, clinicians can now offer more targeted treatment plans that optimize outcomes. This trend is contributing to more effective management of hypogonadism, reducing the risk of side effects associated with standardized treatment regimens. Personalized approaches allow for better patient satisfaction and improved clinical outcomes, making it a key development in the market.
• Use of Telemedicine for Hormone Therapy Management: Telemedicine has gained significant traction, particularly in the context of managing male hypogonadism therapies. Virtual consultations, remote monitoring, and online prescription services allow patients to manage their testosterone therapy from the comfort of their homes, reducing the need for frequent in-person visits. This trend is especially beneficial for patients in remote or underserved areas who may not have easy access to healthcare providers. Telemedicine platforms are expected to become more integrated into the male hypogonadism management process, improving patient convenience and compliance with treatment regimens.
• Growth of Over-the-Counter (OTC) Testosterone Boosters: There is a growing market for over-the-counter testosterone boosters and supplements, especially among men looking for mild treatments to address symptoms of low testosterone. These products, which often contain herbal ingredients, vitamins, and minerals, are being marketed as natural solutions for improving testosterone levels without prescription-based treatments. While the efficacy of OTC testosterone boosters may vary, their increasing popularity reflects a shift in consumer preferences toward less invasive, self-managed treatment options. This trend is creating both opportunities and challenges in the market, as it shifts focus away from traditional therapies.
• Focus on Men's Health Awareness Campaigns: Awareness campaigns aimed at educating men about the symptoms and consequences of hypogonadism are gaining momentum, particularly in developed regions. These campaigns are playing a significant role in increasing the diagnosis rates of male hypogonadism, encouraging men to seek professional care for low testosterone levels. By addressing common misconceptions and emphasizing the importance of testosterone for overall well-being, such initiatives are improving patient engagement and treatment adoption. The rise in men's health awareness is expected to continue to drive the market as more individuals recognize the need for proper diagnosis and therapy.

These emerging trends indicate that the male hypogonadism therapy market is undergoing significant changes. From long-acting therapies and personalized treatment approaches to the integration of telemedicine and the rise of OTC testosterone boosters, the market is becoming more patient-centric and accessible. Additionally, men's health awareness campaigns are contributing to greater recognition and diagnosis of the condition. Collectively, these trends are reshaping the market, expanding opportunities for innovation, improving patient outcomes, and enhancing the overall management of male hypogonadism.

Recent Developments in the Male Hypogonadism Therapy Market

The global male hypogonadism therapy market is experiencing rapid evolution, fueled by technological advancements, regulatory changes, and shifts in patient demographics. Here are five key developments that are shaping the market landscape:

• FDA Approvals of New Testosterone Therapies: The approval of new testosterone replacement therapies by the U.S. FDA has expanded treatment options for men suffering from hypogonadism. New formulations, such as testosterone nasal sprays, transdermal patches, and longer-acting injectable treatments, have improved patient compliance and convenience. These innovations provide patients with more tailored and less invasive alternatives to traditional therapies, enhancing the overall treatment experience. The regulatory approval of such products has made testosterone therapy more accessible and acceptable in mainstream healthcare.
• Development of Non-Invasive Testosterone Delivery Methods: A significant shift in the male hypogonadism therapy market has been the development of non-invasive testosterone delivery methods, such as testosterone gels, creams, and patches. These therapies offer more convenient and comfortable alternatives to traditional injections, which require healthcare professional administration. The growing preference for these products is driven by their ease of use and the ability to administer them at home. Non-invasive delivery methods are helping to reduce treatment discontinuation rates and improve patient outcomes, making them a key development in the market.
• Telemedicine Integration in Hypogonadism Therapy: Telemedicine is transforming the management of male hypogonadism therapies. With the increasing demand for remote healthcare services, telemedicine platforms are being used to provide consultations, monitor patient progress, and adjust treatment plans. This approach has made it easier for men to access testosterone replacement therapies without the need for frequent in-person visits. The adoption of telemedicine has increased access to care, especially in rural or underserved areas, and is expected to continue growing, particularly as online prescriptions for testosterone therapy become more common.
• Shift Toward Personalized Medicine: Advances in genetic testing and biomarker identification are driving a shift towards personalized medicine in the treatment of male hypogonadism. Personalized medicine allows for more precise and tailored treatment plans, improving patient outcomes and minimizing risks. By using genetic data, healthcare providers can better understand how a patient's body will respond to specific testosterone therapies, leading to optimized treatment strategies. This trend is contributing to improved patient satisfaction and better overall management of hypogonadism.
• Expanding Access in Emerging Markets: The global market for male hypogonadism therapies is expanding into emerging markets, particularly in regions like India and China. As awareness of male hypogonadism increases and healthcare access improves, there is growing demand for testosterone replacement therapies. Pharmaceutical companies are working to increase their presence in these markets by offering affordable treatment options and partnering with local healthcare providers. The expansion of healthcare infrastructure in these regions is expected to drive significant growth in the male hypogonadism therapy market.

These developments highlight the ongoing transformation of the male hypogonadism therapy market. Innovations in treatment formulations, the rise of telemedicine, personalized medicine, and expanding market access in emerging regions are creating new opportunities for growth. As these trends continue to evolve, the market is expected to witness further advancements that will improve treatment outcomes and patient quality of life.

Strategic Growth Opportunities in the Male Hypogonadism Therapy Market

The global male hypogonadism therapy market is growing rapidly due to increasing awareness of testosterone deficiency and advancements in treatment options. Male hypogonadism, often characterized by low testosterone levels, affects a significant portion of the male population, particularly in older age groups. With technological innovations and more accessible treatments, the market is positioned for continued expansion. Strategic growth opportunities exist across various applications, driven by factors such as patient demand, regulatory approval, and healthcare infrastructure improvements. These opportunities offer pathways for companies to expand their product offerings and reach new patient populations, particularly in emerging markets.

• Personalized Medicine for Hypogonadism Treatment: Personalized medicine offers a growth opportunity by tailoring testosterone replacement therapies to individual patient needs. Genetic and biomarker testing can help healthcare providers create treatment plans that optimize efficacy and minimize side effects. This approach allows for more targeted therapy, improving patient compliance and satisfaction. Personalized treatment also reduces the risks of improper dosage or adverse reactions, making it an appealing option for managing male hypogonadism. As demand for customized care increases, pharmaceutical companies that incorporate personalized medicine into their strategies will be well-positioned to capture a larger share of the market.
• Telemedicine and Remote Monitoring Solutions: The rise of telemedicine presents a significant growth opportunity in the male hypogonadism therapy market. With more patients seeking remote consultations and management, telehealth platforms are becoming crucial for delivering testosterone therapies. Telemedicine allows for remote monitoring of testosterone levels, adjustments to therapy, and easy access to prescriptions without the need for frequent in-person visits. This is particularly beneficial for men in rural or underserved areas. As telemedicine technology continues to improve and become more widely accepted, it is expected to drive growth in the male hypogonadism therapy market, making treatments more accessible and cost-effective.
• Emerging Markets Expansion: As awareness of male hypogonadism increases globally, emerging markets represent a key growth opportunity for testosterone replacement therapies. In countries like India, China, and Brazil, the rising middle class, improved healthcare access, and an aging male population are contributing to increased demand for hypogonadism treatments. Companies that expand their presence in these regions, by offering affordable therapies and educating healthcare providers, can capture significant market share. With government support for better healthcare infrastructure, pharmaceutical companies can benefit from entering these high-growth markets and tapping into a large, underserved population.
• Innovative Testosterone Delivery Systems: Advancements in testosterone delivery systems offer a growth opportunity for the male hypogonadism market. Traditional methods like injections are being supplemented with more convenient alternatives, such as transdermal patches, subcutaneous pellets, and topical gels. These novel systems offer improved patient compliance and comfort, addressing the challenges of injection-based treatments. By enhancing delivery methods and reducing side effects, these innovations are likely to lead to increased adoption of testosterone therapies. Companies focusing on the development and distribution of these alternative therapies are expected to benefit from a growing demand for easier-to-administer treatments.
• Over-the-Counter (OTC) Testosterone Boosters: The market for over-the-counter testosterone boosters is growing as more men seek to address mild testosterone deficiencies with less invasive treatments. OTC testosterone boosters, which often include natural ingredients and herbal supplements, are appealing to men who may not yet require prescription-based therapies. While the efficacy of these products varies, the growing popularity of OTC supplements reflects an increasing demand for non-prescription solutions. This trend creates an opportunity for companies to develop and market effective, safe OTC options. As consumer awareness rises, the OTC testosterone booster market will likely continue to expand, complementing prescription therapies.

These strategic growth opportunities personalized medicine, telemedicine solutions, expansion into emerging markets, innovative testosterone delivery systems, and the OTC testosterone booster segment are shaping the future of the male hypogonadism therapy market. As these trends evolve, pharmaceutical companies can tap into new revenue streams, increase patient engagement, and improve treatment outcomes. The increasing availability and adoption of various treatment options ensure that the market will continue to grow and diversify, meeting the needs of a broader population.

Male Hypogonadism Therapy Market Driver and Challenges

The global male hypogonadism therapy market is influenced by a complex array of technological, economic, and regulatory factors. On the one hand, advances in treatment options, increasing awareness of testosterone deficiency, and improved healthcare access are driving the growth of the market. On the other hand, regulatory hurdles, the cost of treatments, and concerns about the safety of testosterone therapy present challenges. Understanding these drivers and challenges is essential for companies to navigate the competitive landscape and optimize their strategies in the male hypogonadism market.

The factors responsible for driving the male hypogonadism therapy market include:

1. Advancements in Testosterone Replacement Therapies Advancements in testosterone replacement therapies are one of the primary drivers of growth in the male hypogonadism market. New delivery methods, such as long-acting injectable formulations, transdermal patches, and subcutaneous pellets, offer more convenient and effective options compared to traditional treatments. These innovations improve patient compliance and reduce the frequency of administration, making them more attractive for both patients and healthcare providers. As pharmaceutical companies continue to develop novel therapies, the market will likely experience increased adoption and expanded patient populations.

2. Growing Awareness and Diagnosis of Male Hypogonadism Increased awareness of male hypogonadism, especially among older men, is a significant driver in the market. As the population ages, more men are seeking medical advice for symptoms of low testosterone, such as fatigue, decreased libido, and mood swings. With heightened awareness through marketing campaigns, social media, and healthcare advocacy, there has been an increase in the number of diagnoses. As more men become informed about the condition, the demand for testosterone replacement therapies is expected to grow, contributing to the overall market expansion.

3. Aging Male Population The aging population is a critical driver in the male hypogonadism therapy market. Testosterone levels naturally decline with age, and as the male population ages, the prevalence of hypogonadism is rising. In developed countries, the proportion of older men is growing, leading to higher demand for testosterone replacement therapies. This trend is particularly evident in markets like North America and Europe. Pharmaceutical companies are focusing on developing treatments that cater to the needs of this aging demographic, creating opportunities for growth in the market.

4. Technological Advancements in Diagnosis and Treatment Technological advancements, such as improved diagnostic tests for testosterone levels and the development of personalized treatment regimens, are driving the market. Innovations in biomarkers and genetic testing allow healthcare providers to identify hypogonadism more accurately and tailor treatment plans for individual patients. These advancements not only improve patient outcomes but also promote greater patient engagement in managing their health. As technology continues to evolve, the market for male hypogonadism therapies will benefit from more accurate diagnoses and better-targeted treatments.

5. Increased Access to Healthcare As healthcare systems improve globally, particularly in emerging markets, access to treatments for male hypogonadism is expanding. Countries with large populations, like India and China, are seeing a rise in demand for testosterone therapies as healthcare access improves and awareness of the condition grows. Increased insurance coverage, government-sponsored healthcare programs, and advancements in telemedicine have made treatments more accessible to a broader population. This growing accessibility is expected to fuel the market growth in regions with previously underserved populations.

Challenges in the male hypogonadism therapy market are:

1. Regulatory Hurdles and Approval Delays One of the key challenges facing the male hypogonadism therapy market is regulatory hurdles. The approval process for new testosterone replacement therapies can be lengthy and complicated. In many markets, regulatory bodies such as the FDA and EMA impose strict requirements on clinical trials and safety data before approving new drugs. These delays in approval can limit the speed at which new therapies enter the market and slow overall market growth. Additionally, regulatory uncertainty in certain regions can create barriers to market entry for pharmaceutical companies.

2. Safety Concerns and Side Effects Despite the growing use of testosterone replacement therapies, safety concerns continue to be a challenge in the market. Long-term use of testosterone has been associated with risks such as cardiovascular events, prostate cancer, and liver issues. As a result, patients and healthcare providers are cautious about the risks of testosterone therapy. This has led to stricter regulations and more conservative treatment guidelines. Companies must invest in research to ensure the safety of their products and address patient concerns about the side effects of testosterone therapies.

3. High Treatment Costs The high cost of testosterone replacement therapies is another significant challenge, particularly in emerging markets where affordability is a key concern. Injectable formulations, in particular, can be expensive, and long-term treatments may lead to substantial healthcare costs. In some cases, patients may be unable to afford these therapies, especially if they lack insurance coverage. While generic versions of testosterone treatments are becoming available, price remains a barrier in certain markets. Addressing the cost of treatments will be crucial for increasing adoption, particularly in developing regions.

The major drivers and challenges in the male hypogonadism therapy market are shaping its future growth trajectory. Technological advancements, increasing awareness, and an aging population are significant drivers, offering opportunities for market expansion. However, challenges such as regulatory hurdles, safety concerns, and high treatment costs must be addressed for the market to continue growing. Companies that can navigate these challenges while leveraging the emerging opportunities will be well-positioned to succeed in the evolving landscape of the male hypogonadism therapy market.

List of Male Hypogonadism Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies male hypogonadism therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the male hypogonadism therapy companies profiled in this report include-

• Eli Lilly
• Pfizer
• AbbVie
• Novo Nordisk
• Merck KGaA

Male Hypogonadism Therapy Market by Segment

The study includes a forecast for the global male hypogonadism therapy market by type, application, and region.

Male Hypogonadism Therapy Market by Type [Value from 2019 to 2031]:

• Parenteral
• Transdermal
• Oral
• Others

Male Hypogonadism Therapy Market by Application [Value from 2019 to 2031]:

• Hospitals
• Drugstores
• Others

Male Hypogonadism Therapy Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Male Hypogonadism Therapy Market

The global male hypogonadism therapy market has seen considerable advancements in recent years, driven by increasing awareness of the condition and new treatment options. Male hypogonadism, characterized by low testosterone levels, affects a significant portion of the male population, particularly in aging men. Key developments in this market are being shaped by advancements in therapeutic approaches, novel drug formulations, and growing market access in emerging economies. Furthermore, regulatory approval processes and technological innovations continue to transform the treatment landscape, improving the quality of life for individuals suffering from the condition.

• United States: The United States continues to lead the global male hypogonadism therapy market. Recent developments include a surge in demand for testosterone replacement therapy (TRT) options such as topical gels, injections, and subcutaneous pellets. Additionally, regulatory bodies like the FDA have approved several new testosterone formulations with better efficacy and fewer side effects. The trend towards personalized medicine and increased access to male hormone therapy through telemedicine platforms have also boosted market growth. Despite concerns over the safety and side effects of long-term testosterone use, the U.S. remains a dominant market, driven by a high prevalence of the condition and increasing public awareness.
• China: In China, the male hypogonadism therapy market is witnessing growth as awareness of testosterone deficiency and related conditions improves. With a large aging population, there has been a noticeable increase in the diagnosis of male hypogonadism, leading to a rise in the demand for testosterone replacement therapies. The Chinese government has also made efforts to promote men's health, which has spurred interest in testosterone-based therapies. However, the market faces challenges related to regulatory approvals, market access in rural areas, and traditional Chinese medicine alternatives that could slow the adoption of Western therapeutic practices for hypogonadism.
• Germany: Germany's male hypogonadism therapy market is well-established, driven by a high level of healthcare infrastructure and awareness. Recent developments include the approval of new testosterone delivery systems, such as long-acting injectable formulations and innovative transdermal patches, offering more convenient treatment options for patients. Germany's healthcare system supports greater access to these therapies, contributing to a steady market growth. Moreover, the country's focus on aging population health issues and the emphasis on improving the quality of life for older men is helping to fuel demand for male hypogonadism treatments.
• India: India's male hypogonadism therapy market is gradually expanding due to growing awareness of the condition, particularly in urban areas. The increasing prevalence of obesity, diabetes, and other conditions linked to low testosterone is driving the demand for testosterone replacement therapies. However, challenges such as a lack of awareness in rural areas, economic constraints, and competition from traditional medicine practices pose hurdles. Despite these challenges, the market is showing positive growth, with increasing availability of affordable treatment options and the rising number of healthcare facilities providing specialized care for men's health issues.
• Japan: In Japan, the male hypogonadism therapy market has seen increased interest, primarily driven by the aging population and rising awareness of testosterone-related disorders. Advances in testosterone therapies, such as subcutaneous testosterone pellets and new oral formulations, have gained popularity. Additionally, Japan's healthcare system is known for its efficiency, which supports the availability and adoption of these treatments. However, the market is also facing challenges related to the high cost of testosterone replacement therapies and limited access to specialized care in rural areas. Still, Japan remains a key player in the Asia-Pacific region due to its aging demographic and growing focus on men's health.

Features of the Global Male Hypogonadism Therapy Market

• Market Size Estimates: Male hypogonadism therapy market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Male hypogonadism therapy market size by type, application, and region in terms of value ($B).
• Regional Analysis: Male hypogonadism therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the male hypogonadism therapy market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the male hypogonadism therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the male hypogonadism therapy market by type (parenteral, transdermal, oral, and others), application (hospitals, drugstores, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Male Hypogonadism Therapy Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Parenteral: Trends and Forecast (2019-2031)
• 4.4 Transdermal: Trends and Forecast (2019-2031)
• 4.5 Oral: Trends and Forecast (2019-2031)
• 4.6 Others: Trends and Forecast (2019-2031)

5. Global Male Hypogonadism Therapy Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospitals: Trends and Forecast (2019-2031)
• 5.4 Drugstores: Trends and Forecast (2019-2031)
• 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Male Hypogonadism Therapy Market by Region

7. North American Male Hypogonadism Therapy Market

• 7.1 Overview
• 7.4 United States Male Hypogonadism Therapy Market
• 7.5 Mexican Male Hypogonadism Therapy Market
• 7.6 Canadian Male Hypogonadism Therapy Market

8. European Male Hypogonadism Therapy Market

• 8.1 Overview
• 8.4 German Male Hypogonadism Therapy Market
• 8.5 French Male Hypogonadism Therapy Market
• 8.6 Spanish Male Hypogonadism Therapy Market
• 8.7 Italian Male Hypogonadism Therapy Market
• 8.8 United Kingdom Male Hypogonadism Therapy Market

9. APAC Male Hypogonadism Therapy Market

• 9.1 Overview
• 9.4 Japanese Male Hypogonadism Therapy Market
• 9.5 Indian Male Hypogonadism Therapy Market
• 9.6 Chinese Male Hypogonadism Therapy Market
• 9.7 South Korean Male Hypogonadism Therapy Market
• 9.8 Indonesian Male Hypogonadism Therapy Market

10. ROW Male Hypogonadism Therapy Market

• 10.1 Overview
• 10.4 Middle Eastern Male Hypogonadism Therapy Market
• 10.5 South American Male Hypogonadism Therapy Market
• 10.6 African Male Hypogonadism Therapy Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Male Hypogonadism Therapy Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Eli Lilly
  • Company Overview
  • Male Hypogonadism Therapy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Pfizer
  • Company Overview
  • Male Hypogonadism Therapy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 AbbVie
  • Company Overview
  • Male Hypogonadism Therapy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Novo Nordisk
  • Company Overview
  • Male Hypogonadism Therapy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Merck KGaA
  • Company Overview
  • Male Hypogonadism Therapy Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us